<DOC>
	<DOCNO>NCT01944384</DOCNO>
	<brief_summary>Aim study : The effect aldosterone blockade myocardial remodel hypertensive patient diastolic failing heart remain unclarified . Background : Nearly half patient clinical heart failure ( HF ) normal leave ventricular ejection fraction ( LVEF ) usually present apparent diastolic dysfunction ( DD ) refer diastolic HF ( DHF ) . The renin-angiotensin-aldosterone system establish major pathway operative pathogenesis HF . The effect aldosterone myocardial hypertrophy , fibrosis endothelial dysfunction clearly establish human animal model . Furthermore , model , aldosterone antagonism prevent development myocardial fibrosis independent effect blood pressure myocardial hypertrophy . However , application patient DHF unspecified . In study , hypothesize aldosterone blockade could reverse LV remodel process hypertensive patient DHF . Study protocol : We enroll medically well-controlled hypertensive patient DHF define presence exertional dyspnea HF signs/symptoms , diastolic dysfunction impair tissue-Doppler ( TDI ) derive mitral early annular diastolic velocity ( &lt; 8 cm/s ) , LVEF &gt; 50 % echocardiography . All patient randomize receive spironolactone 25 mg per day least 6 month . At baseline randomization 6 month randomization , investigate Quality-of-life ( QOL ) score Minnesota Living Heart Failure questionnaire ( Chinese version ) , echocardiography couple TDI assess degree LV hypertrophy , myocardial systolic diastolic characteristic . Otherwise , draw blood sample baseline randomization quantify compare several biomarkers currently prove correlated LV hypertrophy , myocardial fibrosis , biomechanical stretch DHF patient , N-terminal pro-brain-type natriuretic peptide , matrix metalloproteinase-2 , carboxy-terminal telopeptide , procollagen type III amino-terminal propeptide , soluble ST2 , galectin-3 . Expected result : Aldosterone antagonism effective hypertensive patient DHF improve quality life , echo-derived myocardial function , reduce ventricular mechanical stretch lessen degree LV hypertrophy myocardial fibrosis .</brief_summary>
	<brief_title>Impacts Aldosterone Blockade Myocardial Remodeling Hypertensive Patients With Diastolic Failing Heart</brief_title>
	<detailed_description>Aim study : The effect aldosterone blockade myocardial remodel hypertensive patient diastolic failing heart remain unclarified . Background : Nearly half patient clinical heart failure ( HF ) normal leave ventricular ejection fraction ( LVEF ) usually present apparent diastolic dysfunction ( DD ) refer diastolic HF ( DHF ) . Hypertensive heart disease occur majority patient DHF , several key aspect heart failure secondary hypertensive heart disease relatively highly prevalent LV hypertrophy , cardiac fibrosis , endothelial dysfunction-mediated myocardial injury cause change local systemic neurohormonal environment , associate LV diastolic dysfunction tissue-Doppler derive systolic myocardial function . The renin-angiotensin-aldosterone system establish major pathway operative pathogenesis HF . The effect aldosterone myocardial hypertrophy , fibrosis endothelial dysfunction clearly establish human animal model . Furthermore , model , aldosterone antagonism prevent development myocardial fibrosis independent effect blood pressure myocardial hypertrophy . However , application patient DHF unspecified . In study , hypothesize aldosterone blockade could reverse LV remodel process hypertensive patient DHF . Study protocol : We enroll medically well-controlled hypertensive patient DHF define presence exertional dyspnea HF signs/symptoms , diastolic dysfunction impair tissue-Doppler ( TDI ) derive mitral early annular diastolic velocity ( &lt; 8 cm/s ) , LVEF &gt; 50 % echocardiography . All patient randomize receive spironolactone 25 mg per day least 6 month . At baseline randomization 6 month randomization , investigate Quality-of-life ( QOL ) score Minnesota Living Heart Failure questionnaire ( Chinese version ) , echocardiography couple TDI assess degree LV hypertrophy , myocardial systolic diastolic characteristic . Otherwise , draw blood sample baseline randomization quantify compare several biomarkers currently prove correlated LV hypertrophy , myocardial fibrosis , biomechanical stretch DHF patient , N-terminal pro-brain-type natriuretic peptide , matrix metalloproteinase-2 , carboxy-terminal telopeptide , procollagen type III amino-terminal propeptide , soluble ST2 , galectin-3 . Expected result : Aldosterone antagonism effective hypertensive patient DHF improve quality life , echo-derived myocardial function , reduce ventricular mechanical stretch lessen degree LV hypertrophy myocardial fibrosis .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>wellcontrolled hypertensive patient diastolic HF define presence diastolic dysfunction , normal LVEF ( &gt; 50 % ) , exertional dyspnea ( â‰§ New York Heart Association functional class II ) HF signs/symptoms fulfil Framingham criterion despite optimal pharmacological therapy secondary hypertension restrictive , constrictive hypertrophic cardiomyopathy moderate ( mitral tricuspid regurgitant jet area/atrial area 20 % ; aortic regurgitant jet tip mitral valve leaflet ) valvular heart diseases chronic atrial fibrillation usage aldosterone antagonist within 3 month chronic pulmonary disease myocardial infarction within 3 month active ischemia need revascularization LVEF le 50 % echocardiography renal failure ( serum creatinine concentration 2.0 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>